Literature DB >> 30595538

SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression.

Jinfang Zhang1, Ming Chen2, Yasheng Zhu3, Xiangpeng Dai1, Fabin Dang1, Junming Ren1, Shancheng Ren3, Yulia V Shulga4, Francisco Beca5, Wenjian Gan1, Fei Wu6, Yu-Min Lin7, Xiaobo Zhou8, James A DeCaprio9, Andrew H Beck1, Kun Ping Lu7, Jiaoti Huang10, Cheryl Zhao11, Yinghao Sun3, Xu Gao12, Pier Paolo Pandolfi13, Wenyi Wei14.   

Abstract

Frequent SPOP mutation defines the molecular feature underlying one of seven sub-types of human prostate cancer (PrCa). However, it remains largely elusive how SPOP functions as a tumor suppressor in PrCa. Here, we report that SPOP suppresses stem cell traits of both embryonic stem cells and PrCa cells through promoting Nanog poly-ubiquitination and subsequent degradation. Mechanistically, Nanog, but not other pluripotency-determining factors including Oct4, Sox2, and Klf4, specifically interacts with SPOP via a conservative degron motif. Importantly, cancer-derived mutations in SPOP or at the Nanog-degron (S68Y) disrupt SPOP-mediated destruction of Nanog, leading to elevated cancer stem cell traits and PrCa progression. Notably, we identify the Pin1 oncoprotein as an upstream Nanog regulator that impairs its recognition by SPOP and thereby stabilizes Nanog. Thus, Pin1 inhibitors promote SPOP-mediated destruction of Nanog, which provides the molecular insight and rationale to use Pin1 inhibitor(s) for targeted therapies of PrCa patients with wild-type SPOP.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Nanog; Pin1; PrCa; SPOP; phosphorylation; prostate cancer; stem cell; ubiquitination

Mesh:

Substances:

Year:  2018        PMID: 30595538      PMCID: PMC6462403          DOI: 10.1016/j.devcel.2018.11.035

Source DB:  PubMed          Journal:  Dev Cell        ISSN: 1534-5807            Impact factor:   12.270


  68 in total

1.  Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array.

Authors:  Wennuan Liu; Baoli Chang; Jurga Sauvageot; Latchezar Dimitrov; Marta Gielzak; Tao Li; Guifang Yan; Jishan Sun; Jielin Sun; Tamara S Adams; Aubrey R Turner; Jin Woo Kim; Deborah A Meyers; Siqun Lilly Zheng; William B Isaacs; Jianfeng Xu
Journal:  Genes Chromosomes Cancer       Date:  2006-11       Impact factor: 5.006

2.  The lethal clone in prostate cancer: redefining the index.

Authors:  Christopher E Barbieri; Francesca Demichelis; Mark A Rubin
Journal:  Eur Urol       Date:  2014-01-02       Impact factor: 20.096

3.  Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation.

Authors:  Nahyun Choi; Boyu Zhang; Li Zhang; Michael Ittmann; Li Xin
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

4.  Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.

Authors:  Chuandong Geng; Kimal Rajapakshe; Shrijal S Shah; John Shou; Vijay Kumar Eedunuri; Christopher Foley; Warren Fiskus; Mahitha Rajendran; Sue Anne Chew; Martin Zimmermann; Richard Bond; Bin He; Cristian Coarfa; Nicholas Mitsiades
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

5.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.

Authors:  Chuandong Geng; Bin He; Limei Xu; Christopher E Barbieri; Vijay Kumar Eedunuri; Sue Anne Chew; Martin Zimmermann; Richard Bond; John Shou; Chao Li; Mirjam Blattner; David M Lonard; Francesca Demichelis; Cristian Coarfa; Mark A Rubin; Pengbo Zhou; Bert W O'Malley; Nicholas Mitsiades
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-04       Impact factor: 11.205

Review 6.  MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy.

Authors:  Steffan T Nawrocki; Patrick Griffin; Kevin R Kelly; Jennifer S Carew
Journal:  Expert Opin Investig Drugs       Date:  2012-07-16       Impact factor: 6.206

Review 7.  Emerging role of nanog in tumorigenesis and cancer stem cells.

Authors:  Luis E Iv Santaliz-Ruiz; Xiujie Xie; Matthew Old; Theodoros N Teknos; Quintin Pan
Journal:  Int J Cancer       Date:  2014-01-13       Impact factor: 7.396

8.  Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon-mediated immunity.

Authors:  Adrian Tun-Kyi; Greg Finn; Alex Greenwood; Michael Nowak; Tae Ho Lee; John M Asara; George C Tsokos; Kate Fitzgerald; Elliot Israel; Xiaoxia Li; Mark Exley; Linda K Nicholson; Kun Ping Lu
Journal:  Nat Immunol       Date:  2011-07-10       Impact factor: 25.606

9.  Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast.

Authors:  Alessandra Rustighi; Alessandro Zannini; Luca Tiberi; Roberta Sommaggio; Silvano Piazza; Giovanni Sorrentino; Simona Nuzzo; Antonella Tuscano; Vincenzo Eterno; Federica Benvenuti; Libero Santarpia; Iannis Aifantis; Antonio Rosato; Silvio Bicciato; Alberto Zambelli; Giannino Del Sal
Journal:  EMBO Mol Med       Date:  2013-12-15       Impact factor: 12.137

10.  A luminal epithelial stem cell that is a cell of origin for prostate cancer.

Authors:  Xi Wang; Marianna Kruithof-de Julio; Kyriakos D Economides; David Walker; Hailong Yu; M Vivienne Halili; Ya-Ping Hu; Sandy M Price; Cory Abate-Shen; Michael M Shen
Journal:  Nature       Date:  2009-09-09       Impact factor: 49.962

View more
  21 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 2.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

Review 3.  Signaling Pathways and Targeted Therapies for Stem Cells in Prostate Cancer.

Authors:  Madhuvanthi Giridharan; Vasu Rupani; Satarupa Banerjee
Journal:  ACS Pharmacol Transl Sci       Date:  2022-03-30

Review 4.  SPOP and cancer: a systematic review.

Authors:  Alison Clark; Marieke Burleson
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 5.  Molecular Chaperones in Cancer Stem Cells: Determinants of Stemness and Potential Targets for Antitumor Therapy.

Authors:  Alexander Kabakov; Anna Yakimova; Olga Matchuk
Journal:  Cells       Date:  2020-04-06       Impact factor: 6.600

Review 6.  The ubiquitin ligase adaptor SPOP in cancer.

Authors:  Matthew J Cuneo; Tanja Mittag
Journal:  FEBS J       Date:  2019-09-18       Impact factor: 5.542

7.  Susceptibility-Associated Genetic Variation in NEDD9 Contributes to Prostate Cancer Initiation and Progression.

Authors:  Dong Han; Jude N Owiredu; Bridget M Healy; Muqing Li; Maryam Labaf; Jocelyn S Steinfeld; Susan Patalano; Shuai Gao; Mingyu Liu; Jill A Macoska; Kourosh Zarringhalam; Kellee R Siegfried; Xin Yuan; Timothy R Rebbeck; Changmeng Cai
Journal:  Cancer Res       Date:  2021-02-25       Impact factor: 12.701

8.  TGF-β signaling regulates SPOP expression and promotes prostate cancer cell stemness.

Authors:  Chenchen Jiao; Tong Meng; Chenyu Zhou; Xinbo Wang; Ping Wang; Meiling Lu; Xiao Tan; Qing Wei; Xin Ge; Jiali Jin
Journal:  Aging (Albany NY)       Date:  2020-05-01       Impact factor: 5.682

Review 9.  DAXX in cancer: phenomena, processes, mechanisms and regulation.

Authors:  Iqbal Mahmud; Daiqing Liao
Journal:  Nucleic Acids Res       Date:  2019-09-05       Impact factor: 16.971

10.  SPOP suppresses pancreatic cancer progression by promoting the degradation of NANOG.

Authors:  Peng Tan; Yunke Xu; Yichao Du; Lile Wu; Bing Guo; Shiyao Huang; Jinhui Zhu; Bo Li; Fujun Lin; Lei Yao
Journal:  Cell Death Dis       Date:  2019-10-17       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.